BMS: Sales For Opdivo Are Flying High

Recent approvals for Bristol-Myers Squibb's PD-1 inhibitor Opdivo (nivolumab) resulted in accelerated sales in the second half, with rapid adoption in new indications, said CEO Giovanni Caforio at the J.P. Morgan conference in San Francisco this week.